CorMedix Inc. | Small-cap | Healthcare
$13.03
2.20%
| CorMedix Stock Comparison:
CorMedix vs VertexCorMedix vs RegeneronCorMedix vs AdaptiveCorMedix vs Travere TherapeuticsCorMedix vs Immunocore HoldingsCorMedix vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 39.1M
Gross Profit 37.5M 95.91%
Operating Income 20.1M 51.50%
Net Income 20.6M 52.82%
EPS (Diluted) $0.30

Balance Sheet Metrics

Total Assets 149.6M
Total Liabilities 34.7M
Shareholders Equity 114.9M
Debt to Equity 0.30

Cash Flow Metrics

Operating Cash Flow 21.7M
Free Cash Flow 19.7M

Revenue & Profitability Trend

CorMedix Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i43.5M065.4K190.9K239.2K
Cost of Goods Sold i3.2M03.7K148.9K204.8K
Gross Profit i40.3M061.7K42.0K34.4K
Gross Margin % i92.7%0.0%94.3%22.0%14.4%
Operating Expenses
Research & Development i3.9M13.2M10.7M13.1M13.4M
Selling, General & Administrative i58.7M35.8M20.0M16.3M13.9M
Other Operating Expenses i-----
Total Operating Expenses i62.6M49.0M30.7M29.5M27.3M
Operating Income i-22.4M-49.0M-30.6M-29.4M-27.2M
Operating Margin % i-51.4%0.0%-46,819.9%-15,417.5%-11,378.4%
Non-Operating Items
Interest Income i2.6M2.7M326.0K14.4K116.1K
Interest Expense i36.4K34.3K26.5K15.9K33.2K
Other Non-Operating Income489.2K-29.0K37.1K-21.3K-59.2K
Pre-tax Income i-19.3M-46.3M-30.3M-29.5M-27.2M
Income Tax i-1.4M0-585.6K-1.3M-5.2M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-17.9M-46.3M-29.7M-28.2M-22.0M
Net Margin % i-41.2%0.0%-45,409.9%-14,774.7%-9,207.7%
Key Metrics
EBITDA i-18.9M-46.2M-30.2M-29.4M-27.0M
EPS (Basic) i$-0.30$-0.91$-0.74$-0.75$-0.77
EPS (Diluted) i$-0.30$-0.91$-0.74$-0.75$-0.77
Basic Shares Outstanding i5887158250902931402742733766608128561963
Diluted Shares Outstanding i5887158250902931402742733766608128561963

Income Statement Trend

CorMedix Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i40.7M43.6M43.1M53.3M41.9M
Short-term Investments i11.0M32.4M15.6M12.1M4.4M
Accounts Receivable i51.7M-045.4K3.4K
Inventory i7.6M2.1M03.0K143.6K
Other Current Assets2.4M882.2K623.7K770.5K-
Total Current Assets i114.6M79.5M59.6M66.5M48.2M
Non-Current Assets
Property, Plant & Equipment i3.0M3.0M2.8M2.7M1.4M
Goodwill i1.8M----
Intangible Assets i1.8M----
Long-term Investments-----
Other Non-Current Assets105.4K103.1K102.3K102.3K-
Total Non-Current Assets i4.3M2.6M2.5M2.5M1.1M
Total Assets i118.8M82.1M62.0M68.9M49.3M
Liabilities
Current Liabilities
Accounts Payable i1.7M4.3M2.2M2.2M1.1M
Short-term Debt i167.9K150.6K134.8K121.4K109.1K
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i33.8M11.4M6.3M5.3M4.2M
Non-Current Liabilities
Long-term Debt i349.1K517.0K667.6K802.4K923.7K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i349.1K517.0K667.6K802.4K923.7K
Total Liabilities i34.2M11.9M7.0M6.1M5.1M
Equity
Common Stock i64.4K54.9K42.8K38.1K33.6K
Retained Earnings i-339.6M-321.7M-275.4M-245.7M-217.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i84.7M70.1M55.1M62.8M44.2M
Key Metrics
Total Debt i517.0K667.6K802.4K923.8K1.0M
Working Capital i80.7M68.0M53.2M61.1M44.0M

Balance Sheet Composition

CorMedix Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-17.9M-46.3M-29.7M-28.2M-22.0M
Depreciation & Amortization i309.8K70.8K84.6K61.9K128.0K
Stock-Based Compensation i6.1M5.5M4.1M5.0M2.5M
Working Capital Changes i-60.0M-163.7K-82.8K1.1M228.8K
Operating Cash Flow i-71.3M-40.8M-25.5M-21.9M-19.1M
Investing Activities
Capital Expenditures i-115.7K-327.3K-219.4K-1.4M-112.6K
Acquisitions i-----
Investment Purchases i-26.8M-77.1M-31.1M-15.3M-8.5M
Investment Sales i48.1M60.4M27.6M7.6M16.1M
Investing Cash Flow i21.2M-17.1M-3.7M-9.1M7.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i18.6M55.6M17.8M41.5M39.7M
Free Cash Flow i-50.7M-38.7M-24.6M-22.6M-22.1M
Net Change in Cash i-31.5M-2.2M-11.4M10.4M28.0M

Cash Flow Trend

CorMedix Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 15.90
Forward P/E 25.83
Price to Book 4.19
Price to Sales 7.62
PEG Ratio -0.07

Profitability Ratios

Profit Margin 42.11%
Operating Margin 49.18%
Return on Equity 38.35%
Return on Assets 19.87%

Financial Health

Current Ratio 7.82
Debt to Equity 0.20
Beta 1.77

Per Share Data

EPS (TTM) $0.78
Book Value per Share $2.96
Revenue per Share $1.92

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
crmd989.6M15.904.1938.35%42.11%0.20
Vertex 101.6B28.195.9122.77%31.86%8.89
Regeneron 60.8B14.451.9915.34%31.37%9.04
Adaptive 2.0B-11.9010.88-57.60%-59.07%121.39
Travere Therapeutics 1.9B-5.3058.80-705.73%-50.64%1,220.18
Immunocore Holdings 1.9B-36.474.82-5.43%-5.70%112.35

Financial data is updated regularly. All figures are in the company's reporting currency.